Induction immunosuppression for lung transplantation with OKT3

Annals of Thoracic Surgery

Volumn 67, Issue 1, 1999, Pages 187-193

  Wain, John C ^a   Wright, Cameron D ^a   Ryan, Daniel P ^a   Zorb, Susan L ^a   Mathisen, Douglas J ^a   Ginns, Leo C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; AZATHIOPRINE; CLOTRIMAZOLE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; FLUCONAZOLE; GANCICLOVIR; METHYLPREDNISOLONE; OKT 3; PREDNISONE; STEROID; THYMOCYTE ANTIBODY; VANCOMYCIN;

ADULT; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; BRONCHIOLITIS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STEROID THERAPY; TRANSBRONCHIAL BIOPSY; TREATMENT OUTCOME; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; BRONCHIOLITIS OBLITERANS; FEMALE; GRAFT REJECTION; HEMODYNAMIC PROCESSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LENGTH OF STAY; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MUROMONAB-CD3; POSTOPERATIVE COMPLICATIONS; RESPIRATORY TRACT DISEASES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0032991597     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(98)01308-3     Document Type: Article

References (23)

1. Kung PC, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T-cell surface antigens. Science 1979;206:347-9.
2. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981; 305:308-12.
3. Debure A, Chkoff N, Chatenoud L, et al. One-month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 1988;45:546-53.
4. Cosimi AB, Cho SI, Delmonico FL, Kaplan MM, Rohrer RJ, Jenkins RL. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 1987;43:91-5.
5. Renlund DG, O'Connell JB, Gilbert EM, et al. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Transplantation 1989; 47:599-610.
6. Stratta RJ, Sollinger HW, D'Alessandro AM, Kalayoglu JDP, Belzer FO. OKT3 rescue therapy in pancreas allograft rejection. Diabetes 1989;38(Suppl 1):74-8.
7. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989;46:606-12.
8. Shennib H, Massard G, Reynaud M, Noirclerc M. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation. J Heart Lung Transplant 1994;13:514-9.
9. Calhoon JH, Nichols L, Davis R, et al. Single lung transplantation: factors in postoperative cytomegalovirus infection. J Thorac Cardiovasc Surg 1992;103:21-6.
10. Cooper JD, Patterson GA, Trulock EP, et al. Results of single and bilateral lung transplantation in 131 consecutive recipients. J Thorac Cardiovasc Surg 1994;107:460-71.
11. Bando K, Paradis IL, Komatsu K, et al. Analysis of time-dependent risks for infection, rejection and death after pulmonary transplantation. J Thorac Cardiovasc Surg 1995;109:49-59.
12. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-60.
13. Hughes JH, Mann DR, Hamparian VV. Detection of respiratory synctial virus in clinical specimens by viral culture, direct and indirect immunofluoresence and enzyme immunoassay. J Clin Microbiol 1988;26:588-91.
14. Committee on Infectious Diseases. Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics 1993;92:501-4.
15. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant 1996;15:1-15.
16. Sommers KE, Griffith BP, Hardesty RL, Keenan RJ. Early lung allograft function in twin recipients from the same donor: risk factor analysis. Ann Thorac Surg 1996;62:784-90.
17. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995;60:580-5.
18. Sundaresan S, Trulock EP, Mohanakumar T, et al. Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Ann Thorac Surg 1995;60:1341-7.
19. Duncan SR, Paradis IL, Yousem SA, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992;164:1419-25.
20. Keenan RJ, Lega ME, Dummer JS, et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991;51:433-8.
21. Englund JA, Sullivan CJ, Jordan MD, et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 1988;109:203-8.
22. Everard ML, Milner AD. The respiratory syncytial virus and its role in acute bronchiolitis. Eur J Pediatr 1992;151:638-51.
23. Hohlfeld J, Niedermeyer J, Hamm H, Schafers HJ, Wagner TOF, Fabel H. Seasonal onset of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 1996;15:888-94.